Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of ianalumab and iscalimab in systemic lupus erythematosus
MOH_2018-12-25_004739Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab and iscalimab in systemic lupus erythematosus (SLE) (4 cohorts), sponsored by Novartis. Started Dec 2018; status: active, not recruiting.
02
Drugs
ianalumabiscalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2018-12-25_004739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-25_004739.